慢性胆汁淤积性肝病基础上发生药物性肝损伤的新见解与展望  

New insights and prospects of drug-induced liver injury in the context of chronic cholestatic liver diseases

作　　者：余思邈 王伽伯 肖小河 王睿林 YU Simiao;WANG Jiabo;XIAO Xiaohe;WANG Ruilin(Department of Traditional Chinese Medicine for Liver Diseases,The Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China;School of Traditional Chinese Medicine,Capital Medical University,Beijing 100069,China)

机构地区：[1]中国人民解放军总医院第五医学中心中医肝病科,北京100039 [2]首都医科大学中医药学院,北京100069

出　　处：《临床肝胆病杂志》2025年第2期365-369,共5页Journal of Clinical Hepatology

基　　金：中国医药教育协会2020重大科学攻关问题和医药技术难题(2020KTY001);国家自然科学基金面上项目(81673806)。

摘　　要：慢性胆汁淤积性肝病患者发生疑似药物性肝损伤(DILI)的检测、评估和管理等方面存在诸多挑战,尤其是胆汁淤积性DILI在临床和组织学上可能与潜在的胆汁淤积性肝病的进展难以区分。目前,缺乏慢性胆汁淤积性肝病合并DILI的相关研究与管理规范。本文对慢性胆汁淤积性肝病合并DILI的潜在风险、因果关系及分型标准进行了探讨,以期提高临床工作者对该类疾病的认识,为其防治及管理策略提供参考。Patients with chronic cholestatic liver diseases face numerous challenges in the detection,assessment,and management of suspected drug-induced liver injury(DILI),and in particular,it is difficult to distinguish cholestatic DILI from the progression of underlying cholestatic liver diseases clinically and histologically.Currently,there is a lack of related research and management guidelines for DILI with chronic cholestatic liver diseases.This article discusses the potential risks,causality,and classification criteria for chronic cholestatic liver diseases with DILI,in order to improve the understanding of such diseases among clinicians and provide a reference for prevention,treatment,and management strategies.

关 键 词：胆汁淤积性肝病 化学性与药物性肝损伤 诊断 鉴别 

分 类 号：R57[医药卫生—消化系统]